Immunogenicity of a 2-Dose Regimen of Moderna MRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
Overview
Overview
Journal
J Infect Dis
Publisher
Oxford University Press
Specialty
Infectious Diseases
Date
2023 Aug 10
PMID
37561027
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.
References
1.
B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W
. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50.
PMC: 9017870.
DOI: 10.1126/science.abm3425.
View
2.
Atmar R, Lyke K, Deming M, Jackson L, Branche A, El Sahly H
. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022; 386(11):1046-1057.
PMC: 8820244.
DOI: 10.1056/NEJMoa2116414.
View
3.
Link-Gelles R, Ciesla A, Fleming-Dutra K, Smith Z, Britton A, Wiegand R
. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(48):1526-1530.
PMC: 9721148.
DOI: 10.15585/mmwr.mm7148e1.
View
4.
Callaway E
. The next generation of coronavirus vaccines: a graphical guide. Nature. 2023; 614(7946):22-25.
DOI: 10.1038/d41586-023-00220-z.
View